Search
Betrixaban
go.drugbank.com/drugs/DB12364ApprovedBetrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its fa...
Categories: P-glycoprotein substratesSiponimod
go.drugbank.com/drugs/DB12371ApprovedInvestigationalSiponimod, also known as Mayzent, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a sphi...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesLisofylline
go.drugbank.com/drugs/DB12406InvestigationalLisofylline has been investigated for the treatment of Type 1 Diabetes Mellitus.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesOmadacycline
go.drugbank.com/drugs/DB12455ApprovedInvestigationalOmadacycline has been used in trials studying the treatment of Bacterial Pneumonia, Bacterial Infections, Community-Acquired Infections, and Skin Structures and Soft Tissue Infections. Omadacycline represents a significant advance over t...
Categories: P-glycoprotein substratesFavipiravir
go.drugbank.com/drugs/DB12466ApprovedInvestigationalDiscovered by Toyama Chemical Co., Ltd. in Japan, favipiravir is a modified pyrazine analog that was initially approved for therapeutic use in resistant cases of influenza. The antiviral targets RNA-dependent RNA polymerase (RdRp) enzyme...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP2C8 InhibitorsIbrexafungerp
go.drugbank.com/drugs/DB12471ApprovedIbrexafungerp, also known as SCY-078 or MK-3118, is a novel enfumafungin derivative oral triterpene antifungal approved for the treatment of vulvovaginal candidiasis (VVC), also known as a vaginal yeast infection. It was developed out of...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesMirvetuximab soravtansine
go.drugbank.com/drugs/DB12489ApprovedInvestigationalMirvetuximab soravtansine-gynx (IMGN853) is an antibody-drug conjugate (ADC) formed by a monoclonal antibody (M9346A) that targets folate receptor alpha (FRα), covalently joined by a cleavable disulfide linker to the genotoxic compound D...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesLucinactant
go.drugbank.com/drugs/DB04897ApprovedIt contains sinapultide, a novel, hydrophobic, 21-amino acid peptide (leucine and lysine repeating units, KL4 peptide) designed to mimic human surfactant protein-B (SB-P).
Flibanserin
go.drugbank.com/drugs/DB04908ApprovedInvestigationalFlibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. In February of 2018 Flibanserin was approved by Health Canada under the brand name Addyi for a si...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsClevidipine
go.drugbank.com/drugs/DB04920ApprovedInvestigationalClevidipine is a dihydropyridine L-type calcium channel blocker that is selective for vascular smooth muscle and is indicated for blood pressure reduction when oral therapy is not an option.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inducers